Molecular and immunogenic characterization of BHK-21 cell line adapted CVS-11 strain of rabies virus and future prospect in vaccination strategy

被引：11

作者：

Patel A.C. ^{[1
]}

Upmanyu V. ^{[2
]}

Ramasamy S. ^{[1
]}

Gupta P.K. ^{[3
]}

Singh R. ^{[4
]}

Singh R.P. ^{[1
]}

机构：

[1] Division of Biological Products, ICAR-Indian Veterinary Research Institute, Izatnagar

[2] Division of Biological Standardization, ICAR-Indian Veterinary Research Institute, Izatnagar

[3] Division of Veterinary Biotechnology, ICAR-Indian Veterinary Research Institute, Izatnagar

[4] Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar

来源：

VirusDisease | 2015年 / 26卷 / 4期

关键词：

Adaptation; BHK-21; CVS; NIH test; Rabies virus; Vaccine;

D O I：

10.1007/s13337-015-0285-5

中图分类号：

学科分类号：

摘要：

Development of a cost effective quality vaccine is a key issue in rabies control programme in developing countries. With this perspective, in the present study, challenge virus standard (CVS)-11 strain of rabies virus was adapted to grow in BHK-21 cells, characterized, compared with other viruses including global vaccine strains and field isolates from Indian subcontinent and China at molecular level. This cell adapted virus was evaluated for the production of cost effective veterinary vaccine. The maximum virus titre achieved was 107 fluorescent focus unit (FFU)/mL at 10th passage level. There was no nucleotide difference in the nucleoprotein (N) and glycoprotein (G) genes after adaptation in cell line. Phylogenetic analysis showed that adapted virus was grouped with global vaccine strains, closest being with other CVS strains but distinct from the Indian field isolates. Global vaccine strains including cell adapted CVS-11 virus have 83–87 % identity at nucleotide level of G gene with Indian field viruses. Growth kinetics of cell culture adapted virus showed that the optimum virus titer (around 107 FFU/mL) could be obtained at around 48 h post infection by co-cultivation method using 0.1 multiplicity of infection inoculums at 37 °C. These findings can be used for up scaling of vaccine production. The protective efficacy of test vaccine produced using 106.95 FFU/mL cell culture harvest showed 1.17 IU/mL relative potency by NIH test. Further, adapted virus was found to be suitable for use in rapid fluorescent focus inhibition test. © 2015, Indian Virological Society.

引用

页码：288 / 296

页数：8

共 36 条

[1]

Aga A.M., Mekonnen Y., Hurisa B., Tesfaye T., Lemma H., Kebede G., Niguse D., Gwold G., Urga K., In vivo and in vitro cross neutralization studies of local rabies virus isolates with ERA based cell culture anti-rabies vaccine produced in Ethiopia, J Vaccines Vaccin, 5, (2014)

[2]

Chavez J.H., Yokosawa L., Oliveira T.F.M., Simoes C.M.O., Zanetti C.R., No association between viral cytopathic effect in McCoy cells and MTT colorimetric assay for the in vitro anti-rabies evaluation, Virus Rev Res, 1, pp. 10-18, (2013)

[3]

Faber M., Pulmanausahakul R., Nagao K., Prosniak M., Rice A.B., Koprowski H., Schnell M.J., Dietzschold B., Identification of viral genomic elements responsible for rabies virus neuroinvasiveness, Proc Natl Acad Sci USA, 101, pp. 16328-16332, (2004)

[4]

Goswami A., Plun-Favreau J., Nicoloyannis N., Sampath G., Siddiqui M.N., Zinsou J.A., The real cost of rabies postexposure treatments, Vaccine, 23, pp. 2970-2976, (2005)

[5]

Guo C., Wang C., Luo S., Zhu S., Li H., Liu Y., Zhou L., Zhang P., Zhang X., Ding Y., Huang W., Wu K., Zhang Y., Rong W., Tian H., The adaptation of a CTN-1 rabies virus strain to high-titered growth in chick embryo cells for vaccine development, Virol J, 11, (2014)

[6]

Gupta P.K., Rai A., Rai N., Saini M., Immunogenicity of a plasmid DNA vaccine encoding glycoprotein gene of rabies virus CVS in mice and dogs, J Immunol Immunopathol, 7, pp. 58-61, (2005)

[7]

Hampson K., Coudeville L., Lembo T., Sambo M., Kieffer A., Attlan M., Barrat J., Blanton J.D., Briggs D.J., Cleaveland S., Costa P., Freuling C.M., Hiby E., Knopf L., Leanes F., Meslin F.X., Metlin A., Miranda M.E., Muller T., Nel L.H., Recuenco S., Rupprecht C.E., Schumacher C., Taylor L., Vigilato M.A.N., Zinsstag J., Dushoff J., Estimating the global burden of endemic canine rabies, PLoS Negl Trop Dis, 9, pp. 1-20, (2015)

[8]

Hurisa B., Mengeshaa A., Newayesilassiea B., Kergaa S., Kebedea G., Bankoviskyb D., Metlinc A., Urgaa K., Production of cell culture based anti-rabies vaccine in Ethiopia, Procedia Vaccinol, 7, pp. 2-7, (2013)

[9]

Iwasaki Y., Wiktor T.J., Koprowski H., Early events of rabies virus replication in tissue cultures. An electron microscopic study, Lab Invest, 28, pp. 142-148, (1973)

[10]

Jagannatha S., Gandhi P.R., Vijayakumar R., Kinetics analysis of beta-propiolactone with tangential flow filtration (TFF) concentrated vero cell derived rabies viral protein, J Biol Sci, 13, pp. 521-527, (2013)

← 1 2 3 4 →